



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/084,615	02/28/2002	Motoo Yamasaki	249-159	4132	
7590 04/20/2004			EXAMINER		
NIXON & VANDERHYE P.C.			BORIN, MICHAEL L		
8th Floor 1100 North Glebe Road			ART UNIT	PAPER NUMBER	
Arlington, VA 22201			1631		
			DATE MAILED: 04/20/2004	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

N
9

Office Action Summary

Application No.	Applicant(s)	
10/084,615	YAMASAKI ET AL.	
Examiner	Art Unit	
Michael Borin	1631	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.

If the period for reply specified above is less than thirty (30) days, a reply will. If NO period for reply is specified above, the maximum statutory period will. Failure to reply within the set or extended period for reply will, by statute, can have reply received by the Office later than three months after the mailing decarried patent term adjustment. See 37 CFR 1.704(b).	apply and will expire SIX (6) MONTHS from the mailing date of this communication. ause the application to become ABANDONED (35 U.S.C. § 133).				
Status					
1) Responsive to communication(s) filed on					
2a) This action is FINAL . 2b) This a	ction is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex	parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) Claim(s) <u>15-33</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn	rfrom consideration.				
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>15-33</u> are subject to restriction and/or e	lection requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accep	ited or b)⊡ objected to by the Examiner.				
Applicant may not request that any objection to the dra	awing(s) be held in abeyance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction	n is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Exar	miner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119					
12) ☐ Acknowledgment is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d) or (f).				
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (
* See the attached detailed Office action for a list of	the certified copies not received.				
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:				

Art Unit: 1631

Part III DETAILED ACTION

Claims 15-33 are currently pending.

Restriction Requirement

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 15(in part), 23, 19-22, drawn to a modified polypeptide, ١.

classified in class 530, subclass 350, in general.

II. Claims 15 (in part), 16-22, drawn to, classified in class 530, subclass

350, in general.

Claims 24-33, drawn to method of treatment, classified in class 514, III.

subclass 02.

The inventions are distinct, each from the other because of the following

reasons:

Groups I and II are drawn to independent and/or patentably distinct peptides since

there is no common core structure identified for the peptide of unknown structure of

Group I and peptide having SEQ ID No. 1 of Group II. Each would be expected to

possess distinctly different structure (e.g., amino acid content, secondary and tertiary

structure), and/or physico-chemical properties.

Inventions I,II and III are related as product and process of use. The inventions

can be shown to be distinct if either or both of the following can be shown: (1) the

Art Unit: 1631

process for using the product as claimed can be practiced with another materially

Page 3

different product or (2) the product as claimed can be used in a materially different

process of using that product (MPEP § 806.05(h)). In the instant case the products

as claimed can be used in a materially different processes such as for stimulating cell

cultures in vitro or in peptide synthesis.

Species Requirement

Election of species should be required prior to a search on the merits in all

applications containing both species claims and generic or Markush claims. (MPEP

808.01(a))

Upon election of a single one of the Groups from above the following election

of species is hereby required for the elected Group for the initial search for

examination on merits:

The claims of Groups II or III are individually or dependently directed to a Α.

plurality of disclosed patentably distinct species of peptides having various

substitutions in SEQ ID No. 1. See claims 16-18 for group II and corresponding

claims in Groups III.

В. The claims of Groups I- III are individually or dependently directed to a plurality

of disclosed patentably distinct species of polyalkyleneglycols. See claims 19-22.

Art Unit: 1631

C. The claims of Group III are directed to species of peptide used for the treatment

Page 4

: select between a peptide of unidentified structure(as in claim 24a and 33) or peptide

having (substituted) sequence of SEQ ID No. 1 (for which the species are to be

elected according to (A) above).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species,

even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably

distinct, applicant should submit evidence or identify such evidence now of record

showing the species to be obvious variants or clearly admit on the record that this is

the case. In either instance, if the examiner finds one of the inventions unpatentable

over the prior art, the evidence or admission may be used in a rejection under 35

U.S.C. 103(a) of the other invention.

To be complete, a response to the election of species requirement should

include a proper election along with a listing of all claims readable thereon, including

any claims subsequently added. MPEP 809.02(a).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael Borin whose telephone number is (571) 272-

Art Unit: 1631

0713. Dr. Borin can normally be reached between the hours of 8:30 A.M. to 5:00

Page 5

P.M. EST Monday to Friday. If attempts to reach the examiner by telephone are

unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on

(571) 272-0722.

Any inquiry of a general nature or relating the status of this application should

be directed to the Group receptionist whose telephone number is (571) 272-0549.

MICHAEL BORIN, PH.D PRIMARY EXAMINER

April 15, 2004

mlb